—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Virbac SA (VIRP.PA) — the peer cohort

As of 2026-10-29 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Virbac SA ranks 7 of 9 in its cohort on the Closelooknet composite (49/100) — the cohort is led by Eli Lilly and Company at 65/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
VIRP.PA Virbac SA 49 51 53 59 info 11.2%
LLY Eli Lilly and Company 65 90 91 24 bull 2.5%
ORNAV.HE Orion Oyj A 63 90 84 31 ok 1.3%
ORNBV.HE Orion Oyj B 63 89 84 31 ok 1.2%
SAN.PA Sanofi SA 58 54 70 59 bull 12.5%
AMGN Amgen Inc 57 90 85 40 bull 0.6%
GSK GlaxoSmithKline PLC ADR 54 41 79 55 info 19%
EL.PA EssilorLuxottica S. A. 46 36 48 50 watch 43.8%
ABVX.PA Abivax SA 38 13 53 56 warn 41.7%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-29

Quick answers

Who are Virbac SA's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Sanofi SA (SAN.PA), Amgen Inc (AMGN), GlaxoSmithKline PLC ADR (GSK), EssilorLuxottica S. A. (EL.PA), Abivax SA (ABVX.PA).

How does VIRP.PA score against its peers?

Virbac SA's composite reads 49/100, ranking 7 of 9 in its cohort as of 2026-10-29; the cohort's highest composite is Eli Lilly and Company at 65/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.